Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9485Neoplasms 6599Prostatic Neoplasms 4404Colorectal Neoplasms 3979Lung Neoplasms 3647Carcinoma, Non-Small-Cell Lung 3587Pancreatic Neoplasms 2480Carcinoma, Hepatocellular 2416Leukemia, Myeloid, Acute 2266Multiple Myeloma 2123Stomach Neoplasms 2109Neoplasm Metastasis 1913Head and Neck Neoplasms 1873Ovarian Neoplasms 1778Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1731Brain Neoplasms 1706Rectal Neoplasms 1676Melanoma 1657Colonic Neoplasms 1629Uterine Cervical Neoplasms 1501Leukemia 1500Recurrence 1486Esophageal Neoplasms 1312Glioblastoma 1310Lymphoma, Non-Hodgkin 1205Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1080Lymphoma, Follicular 1069

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Microsatellite-stable Colorectal Cancer × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡